MDxHealthMDXH
MDXH
About: MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Employees: 312
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
12% more capital invested
Capital invested by funds: $47.4M [Q3] → $53.2M (+$5.81M) [Q4]
9% more funds holding
Funds holding: 22 [Q3] → 24 (+2) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
2.82% less ownership
Funds ownership: 48.26% [Q3] → 45.44% (-2.82%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for MDXH.
Financial journalist opinion
Positive
Zacks Investment Research
1 month ago
Down -15.22% in 4 Weeks, Here's Why You Should You Buy the Dip in MDxHealth SA (MDXH)
MDxHealth SA (MDXH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neutral
Seeking Alpha
1 month ago
MDxHealth SA (MDXH) Q4 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants John Fraunces - LifeSci Advisors, IR Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Vidyun Bais - BTIG Dan Brennan - TD Cowen Operator Good day. And welcome to the MDxHealth Fourth Quarter and Full Year 2024 Earnings Call.
Negative
Zacks Investment Research
1 month ago
MDxHealth SA (MDXH) Reports Q4 Loss, Tops Revenue Estimates
MDxHealth SA (MDXH) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.39 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter revenue growth of 28% to $24.7 million 2024 revenue growth of 28% to $90.0 million 68% improvement in adjusted EBITDA in fourth quarter Conference call with Q&A today at 4:30 PM EST / 22:30 CET
Neutral
GlobeNewsWire
3 months ago
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for both periods.
Positive
Seeking Alpha
4 months ago
MDxHealth: Strong Buy On Its Cutting-Edge Urology Diagnostics
MDxHealth SA offers a comprehensive portfolio of precision diagnostics targeting all stages of prostate cancer and advanced UTI detection, addressing a $4.9 billion TAM. The company's flagship products, ConfirmMDx (post-biopsy detection), SelectMDx (pre-biopsy screening), and GPS (treatment planning), are driving clinical adoption. MDxHealth achieved 21% YoY revenue growth in Q3 2024, with management forecasting positive EBITDA by 2025 through disciplined cash management and market penetration.
Neutral
GlobeNewsWire
4 months ago
MDxHealth to Participate in Piper Sandler Healthcare Conference
MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City.
Neutral
Seeking Alpha
5 months ago
MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Michael K. McGarrity - Chief Executive Officer and Director Ron Kalfus - Chief Financial Officer Conference Call Participants Vidyun Bais - BTIG Thomas Flaten - Lake Street Capital Markets Jason Bednar - Piper Sandler Operator Good day, and welcome to the MDxHealth Third Quarter 2024 Earnings Call.
Neutral
GlobeNewsWire
5 months ago
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024
Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K.
Neutral
GlobeNewsWire
6 months ago
MDxHealth Announces Pricing of Offering of Ordinary Shares
MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value (“Ordinary Shares”) in a registered public offering (the “Offering”) at a price to the public of $2.00 per Ordinary Share for total gross proceeds of $40.0 million before deducting commissions and estimated offering expenses. A strategic partner is purchasing 1,500,000 Ordinary Shares in this Offering directly from the Company rather than through the underwriters.
Charts implemented using Lightweight Charts™